Clinical Trials Logo

Growth Hormone Deficiency clinical trials

View clinical trials related to Growth Hormone Deficiency.

Filter by:

NCT ID: NCT00646815 Completed - Clinical trials for Growth Hormone Deficiency

Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone Deficiency

Start date: March 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to further characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic-intramyocellular lipids in patients with growth hormone deficiency (GHD).

NCT ID: NCT00616278 Completed - Clinical trials for Growth Hormone Deficiency

National Cooperative Growth Study in CKD

NCGS
Start date: October 2005
Phase: N/A
Study type: Observational

The purpose of this study is to learn whether growth hormone being administered to children with Chronic Kidney Disease is effective and if it has any side effects.

NCT ID: NCT00600808 Completed - Clinical trials for Growth Hormone Deficiency

Sustained Release Formulation of Somatropin (rDNA Origin)for Injection

Start date: June 2003
Phase: Phase 2/Phase 3
Study type: Interventional

Annualised height velocity after 12/24 months treatment and HV SDS height velocity after 12/24 months treatment expressed as number of standard deviations difference from the mean population height velocity for the appropriate gender and chronological age.

NCT ID: NCT00591760 Completed - Heart Failure Clinical Trials

Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial

Start date: December 2004
Phase: Phase 2
Study type: Interventional

The aim of this study is to investigate the potential benefits of the correction of growth hormone (GH) deficiency with GH replacement therapy in patients with chronic heart failure due to left ventricular systolic dysfunction.

NCT ID: NCT00570011 Completed - Clinical trials for Growth Hormone Deficiency

Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients

Start date: June 1997
Phase: Phase 3
Study type: Interventional

An international study in which patients with GHD were randomized to receive somatropin at a dose of either 3 microg/kg/day or 6 microg/kg/day for the first three months. The dose was then doubled (6 microg/kg/day, LD or 12 microg/kg/day, CD) for the next three-months.

NCT ID: NCT00517062 Completed - Clinical trials for Growth Hormone Deficiency

Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates

Start date: January 2006
Phase: Phase 0
Study type: Interventional

Study hypothesis: Growth hormone (GH), through its generation of free 'bioavailable' insulin-like growth factor (IGF)-I, can improve insulin sensitivity in adults with GH deficiency. Study aims: The purpose of this study is to determine the mechanism of how low dose GH treatment affects the body's sensitivity to insulin actions and whether this low GH dose can affect the body's handling of steroid hormone levels (cortisol clearance) in adults with GH deficiency. Study design: Men and women with confirmed GH deficiency, but not recently been on GH treatment will be invited to participate in this study. The subjects will be assessed at the initial visit to ascertain their suitability before further participating in the study. If suitable, an equal number of men and women will be randomized to receive either low dose GH or placebo injection for 3 months. Before, during and after treatment, the subjects will be assessed at regularly with blood tests, scans and fat biopsies. At the first and final visit, testing will include scans to measure the amount of whole body fat and fat in the stomach area, muscle, and liver; blood tests to measure levels of cortisol, and fat tissue (taken from a biopsy) analysis to measure the density of IGF-I in the muscle; whereas blood tests to examine insulin sensitivity will also be collected. This study will use Genotropin and Genotropin pen devices, and the the data will be analyzed using a computer statistical program where the identity of the subjects will be coded to maintain confidentiality.

NCT ID: NCT00511927 Completed - Heart Failure Clinical Trials

Growth Hormone Deficiency in Chronic Heart Failure: an Observational Study

Start date: July 2010
Phase: N/A
Study type: Observational

Aim of this study is to define the possible detrimental effect of a lack of growth hormone, on the well-being and life expectation of patients affected by heart failure.

NCT ID: NCT00497562 Completed - Fibromyalgia Clinical Trials

Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters)

Start date: May 2004
Phase: Phase 2
Study type: Interventional

There are evidences of functional growth hormone (GH) deficiency, expressed by means of low serum levels of insulin-like growth factor 1 (IGF-1), in a subset of fibromyalgia patients. The efficacy of low GH doses versus placebo has been demonstrated in this population. We assessed the efficacy and safety of GH added to standard therapy compared to standard therapy alone in the treatment of severe, prolonged and well-treated fibromialgya patients with low IGF-1 levels.

NCT ID: NCT00491582 Completed - Clinical trials for Growth Hormone Deficiency

The Effects of Growth Hormone (GH) on Lipid Depots

Start date: July 2007
Phase: N/A
Study type: Interventional

This study aims at investigating the effect of growth hormone on lipid-content of muscle and liver as well as visceral fat mass in relation to insulin sensitivity. In addition, hormonal regulation and free fatty availability is assessed during a physical exercise at 50-60% VO2max. Finally, the value of physical exercise in diagnosing growth hormone deficiency is investigated. Hypothesis: 1) Lipid content of muscle and liver change with physical exercise and exercise capacity and free fatty availability will influence these changes. 2)Growth hormone replacement therapy will predominantly reduce visceral fat mass and increase free fatty availability. 3)Free fatty availability during exercise will be reduced in growth hormone deficient patients 4)Physical exercise may be an alternative way to diagnose growth hormone deficiency

NCT ID: NCT00489294 Completed - Clinical trials for Growth Hormone Deficiency

Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency

Start date: August 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics of Syntropin (a human growth hormone) and to determine the serum concentration of IGF-1 after Syntropin injection.